BRIAN KIMMEL: Open Payments
NPI 1528007176 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$505 in 23 payments from 11 companies in 2025. Trend: 2023 $431 · 2024 $390 · 2025 $505
Food & beverage: $505
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 5 | $98 |
| PFIZER INC. | 4 | $76 |
| AstraZeneca Pharmaceuticals LP | 4 | $74 |
| ACADIA Pharmaceuticals Inc | 1 | $44 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $43 |
| Aimmune Therapeutics, Inc. | 2 | $35 |
| Dexcom, Inc. | 1 | $33 |
| Lundbeck LLC | 1 | $33 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $27 |
| Exact Sciences Corporation | 1 | $25 |
Products named: REXULTI, FARXIGA, NUPLAZID, Kerendia, PAXLOVID, NURTEC ODT, Dexcom G6 Transmitter, CAPLYTA.
Industry payments across PA — which companies pay providers there.
